Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Spago Nanomedical AB's 10-Year ROIIC % for the quarter that ended in Dec. 2025 was 38.47%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Spago Nanomedical AB's 10-Year ROIIC % or its related term are showing as below:
OSTO:SPAGO's 10-Year ROIIC % is ranked better than 80.25% of 1099
companies
in the Biotechnology industry
Industry Median: -19.89
vs OSTO:SPAGO: 38.47
Spago Nanomedical AB (OSTO:SPAGO) 10-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Spago Nanomedical AB 10-Year ROIIC % Related Terms
Spago Nanomedical AB 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Spago Nanomedical AB's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SPAGO vs VRTX, REGN, MRNA: 10-Year ROIIC % Comparison
For the Biotechnology subindustry, Spago Nanomedical AB's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spago Nanomedical AB 10-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spago Nanomedical AB's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Spago Nanomedical AB's 10-Year ROIIC % falls into.
Spago Nanomedical AB's 10-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -26.479 (Dec. 2025) - -6.709 (Dec. 2015) )
/
( 3.851 (Dec. 2025) - 55.244 (Dec. 2015) )
=
-19.77
/
-51.393
=
38.47%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Spago Nanomedical AB (OSTO:SPAGO) has a 10-Year ROIIC % of 38.47 as of Dec. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Spago Nanomedical AB and its competitors. According to the industry distribution chart, Spago Nanomedical AB ranks #217 out of 1099 companies in the Biotechnology industry, placing it in the top 19.7%.
Is Spago Nanomedical AB's 10-Year ROIIC % too high?
Spago Nanomedical AB's current 10-Year ROIIC % is 38.47. Based on the distribution chart, Spago Nanomedical AB ranks #217 out of 1099 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Spago Nanomedical AB has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spago Nanomedical AB's 10-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Spago Nanomedical AB ranks #217 out of 1099 companies for 10-Year ROIIC %. This places Spago Nanomedical AB in the top 20% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Biotechnology company?
A good 10-Year ROIIC % depends on the Biotechnology industry context. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Spago Nanomedical AB and its competitors. Spago Nanomedical AB's current 10-Year ROIIC % is 38.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spago Nanomedical AB stock overvalued right now?
Based on GuruFocus' analysis, Spago Nanomedical AB (OSTO:SPAGO) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.03, compared to a current price of kr0.10 — trading 245% above its estimated fair value. The current 10-Year ROIIC % is 38.47. Spago Nanomedical AB's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Spago Nanomedical AB (OSTO:SPAGO), the current 10-Year ROIIC % is 38.47 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spago Nanomedical AB (OSTO:SPAGO) Overvalued in 2026?
Based on GuruFocus' analysis, Spago Nanomedical AB stock appears to be overvalued.
The current stock price of kr0.10 is trading 245% above its estimated GF Value™ of kr0.03.
GuruFocus considers Spago Nanomedical AB to be Significantly Overvalued.
Key valuation signals for OSTO:SPAGO:
10-Year ROIIC %: 38.47
GF Value™: kr0.03 vs. price of kr0.10 (245% above fair value)
No single metric tells the full story. See the OSTO:SPAGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through the previous detection of tumors and metastases. The Tumorad products focus on the development of a completely new form of radionuclide therapy for tumor-selective radiation therapy of cancer. The company's development projects are based on a platform of polymeric materials with various properties for the precise diagnosis and treatment of life-threatening and debilitating diseases.
32GF Score
Get the complete analysis for OSTO:SPAGO
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SPAGO has been successfully added to your 
